SBP-401 received Orphan Drug Designation(ODD) from the U.S. FDA

Signed a joint R&D agreement with HK inno.N to identify new drug candidates for dyslipidemia (SBP-304)

Received a grant award from Korea Drug Development Fund(KDDF) for Phase I clinical development of a new drug for the National Drug Development Program (SBP-401) Selected as one of Woori Bank’s 12^th Investment Target Companies to Support SME Growth

Phase I IND approval for SBP-401 from MFDS(Ministry of Food and Drug Safety)

Phase I IND approval for SBP-101 from MFDS(Ministry of Food and Drug Safety)

Series C Funds raised $20M

Received a grant award from Korea Drug Development Fund(KDDF) for preclinical candidate identification for immunotherapy by inhibiting STING protein degradation (SBP-105)
Received a grant award from Ministry of Health and Welfare(MOHW) for HMGB1 inhibitor (SBP-101)

Signed an exclusive collaboration and domestic license agreement with Handok to develop and commercialize SBP-101
Received a strategic investment of $2.5M from Handok

Series B Funds raised $21M

Moved the HQ and R&D Center(134, Gwanak-ro)

Series A Funds $3.8M

Moved the Head Quarter(Nakseongdae R&D Center)

Technology proved by government funding

R&D Center certified by government

Venture Business Certificate

Angel Funds

Foundation(Seoul National University)